Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

NCT01967095 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

53

Enrollment

OTHER

Sponsor class

Conditions

EGFR-Mutant Lung Cancer

Interventions

DRUG: erlotinib

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]